Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Recruiting 2Active not recruiting 1

Sponsor Class

NIH 3

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3Other hematologic neoplasm 2

Conditions

Lymphoma, Large B-Cell, Diffuse 4Burkitt Lymphoma 3Prostatic Neoplasms 2Lymphoma, Follicular 2Triple Negative Breast Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Ovarian Neoplasms 1Neoplasms 1Lymphoma, Non-Hodgkin 1Lymphoma, B-Cell 1Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8 1Leukemia, Biphenotypic, Acute 1Endometrial Neoplasms 1Down Syndrome 1Carcinoma, Non-Small-Cell Lung 1Adenocarcinoma 1

Interventions

Cyclophosphamide 19Vincristine 14Methotrexate 13blinatumomab 12Prednisone 12Cytarabine 12merphos 11Specimen Handling 10Mercaptopurine 10prednylidene 9pegaspargase 9deltacortene 9azathiopurine 9N,N-dicyclohexyl-isoborneol-10-sulfonamide 9Dexamethasone 9Leucovorin 8Doxorubicin 8Biopsy 8dexamethasone acetate 7dexamethasone 21-phosphate 7auricularum 7Etoposide 7Calcium Dobesilate 7Thioguanine 6Spinal Puncture 6Daunorubicin 6Asparaginase 6venetoclax 5fludarabine 5calaspargase pegol 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Burkitt Lymphoma × Prednisolone × 30 days × Clear all
NCT06124157 2026-06-03

A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

National Cancer Institute (NCI)

Phase 2 Recruiting
222 enrolled
Lymphoid

Burkitt Lymphoma

NCT06317662 2026-06-03

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

National Cancer Institute (NCI)

Phase 2 Recruiting
153 enrolled
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Leukemia, Biphenotypic, Acute

NCT03914625 2026-05-27

A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia

National Cancer Institute (NCI)

Phase 3 Active not recruiting
6,720 enrolled
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Down Syndrome, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡